AbCellera Biologics Inc.
Close on Oct 19, 2026
- Market cap
- $3.65B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | During market hours | $4.10M | $-0.18 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 11, 2026 | During market hours | $8.30M | $-0.14 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 24, 2026 | During market hours | $44.90M | $-0.03 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | During market hours | $9.00M | $-0.19 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | During market hours | $17.10M | $-0.12 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | During market hours | $4.20M | $-0.15 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | During market hours | $5.10M | $-0.12 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 4, 2024 | During market hours | $6.50M | $-0.17 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | During market hours | $7.30M | $-0.13 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | During market hours | $10.00M | $-0.14 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 20, 2024 | During market hours | $9.20M | $-0.16 | – |
Press releases
Announcements AbCellera Biologics filed with the SEC
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common
Material agreement · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
CO PY RI GH T © A BC EL LE RA AUGUST 10, 2026 ABCL635 PHASE 2 CLINICAL UPDATE
Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
AbCellera Reports Q2 2026 Business Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CO PY RI GH T © A BC EL LE RA AUGUST 5, 2026 Q2 2026 BUSINESS UPDATE
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CO PY RI GH T © A BC EL LE RA MAY 11, 2026 Q1 2026 BUSINESS UPDATE
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
AbCellera Reports Full Year 2025 Business Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CO PY RI GH T © A BC EL LE RA FEBRUARY 24, 2026 FULL YEAR 2025 BUSINESS UPDATE
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
CO PY RI GH T © A BC EL LE RA January 14, 2025 AbCellera Corporate Overview
Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
AbCellera Reports Q3 2025 Business Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CO PY RI GH T © A BC EL LE RA November 6, 2025 Q3 2025 BUSINESS UPDATE
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CO PY RI GH T © A BC EL LE RA August 7, 2025 Q2 2025 BUSINESS UPDATE
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
AbCellera Reports Q1 2025 Business Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CO PY RI GH T © A BC EL LE RA MAY 8, 2025 Q1 2025 BUSINESS UPDATE
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
AbCellera Reports Full Year 2024 Business Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CO PY RI GH T © A BC EL LE RA FEBRUARY 27, 2025 FULL YEAR 2024 BUSINESS UPDATE
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
AbCellera Reports Q3 2024 Business Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CO PY RI GH T © A BC EL LE RA NOVEMBER 4, 2024 Q3 2024 BUSINESS UPDATE
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
AbCellera Reports Q2 2024 Business Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
C O P Y R IG H T © A B C E LL E R A Q2 2024 BUSINESS UPDATE AUGUST 6, 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
AbCellera Reports Q1 2024 Business Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
C O P YR IG H T © A B C E LL E R A Q1 2024 BUSINESS UPDATE MAY 7, 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
AbCellera Reports Full Year 2023 Business Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
C O P YR IG H T © A B C E LL E R A FULL YEAR 2023 BUSINESS UPDATE FEBRUARY 20, 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
C O P Y R IG H T © A B C E LL E R A Q3 2023 BUSINESS UPDATE NOVEMBER 2, 2023
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
AbCellera Reports Q2 2023 Business Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CO PY RI GH T © A BC EL LE RA Q2 2023 BUSINESS UPDATE AUGUST 3, 2023
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K